Many people feel satisfied with smaller portions and experience less interest in food between meals
These data are a cornerstone in our research and build on our understanding of how MASH and cardiometabolic conditions like type 2 diabetes, obesity, dyslipidemia [abnormal fat levels in the blood], and high blood pressure are interrelated. Metabolic dysfunction-associated steatotic liver disease (MASLD), occurs when abnormal amounts of fat accumulate in the liver in the presence of cardiometabolic risk factors such as type 2 diabetes, obesity, high blood levels of cholesterol or other fats, or high blood pressure
discontinue at least 2 months before planned conception) Individuals seeking cholesterol management as the sole therapeutic goal without diabetes or obesity Patients already taking another GLP-1 receptor agonist Healthcare providers should conduct comprehensive cardiovascular risk assessment and ensure patients meet appropriate criteria before prescribing semaglutide
So this was really not on our mind in those days, and it really hasn't got into my mind ever since
Quick math example A 5 mg vial mixed with 2 mL gives 2.5 mg/mL
